Taliglucerase alfa

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Taliglucerase alfa
Clinical data
Legal status ?
ATC code A16AB11
Chemical data
Formula ?

Taliglucerase alfa, commercially known as Elelyso, is a plant-derived enzyme developed by Protalix and Pfizer.[1] The enzyme is a recombinant glucocerebrosidase used to treat Gaucher’s Disease and is the first plant-made pharmaceutical to win approval by the U.S. Food and Drug Administration.[2][3] Expression of proteins in plant cell culture is highly efficient, does not require post-expression modification of the protein, and is not susceptible to contamination by agents such as viruses that are pathological to humans.[4] Using transgenic carrot cells produces a lower cost alternative, and preclinical studies show that the enzyme was well tolerated by patients.[5]

See also[edit]


  1. ^ http://clinicaltrials.gov/ct2/show/NCT00962260
  2. ^ http://www.sciencemag.org/content/320/5875/473.summary
  3. ^ Maxmen, Amy (2 may 2012) First plant-made drug on the market Nature, Biology & Biotechnology, Industry, Retrieved 26 June 2012
  4. ^ http://www.gaucherdisease.org/protalix_drug_information.php
  5. ^ Aviezer, D; Brill-Almon, E; Shaaltiel, Y; Hashmueli, S; Bartfeld, D; Mizrachi, S; Liberman, Y; Freeman, A et al. (2009). "A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation". In Ho, Paulo Lee. PLoS ONE 4 (3): e4792. doi:10.1371/journal.pone.0004792. PMC 2652073. PMID 19277123.